Kos Pharmaceuticals regains Nasdaq listing compliance

By Angela McDaniels

Seattle, Sept. 18 - Kos Pharmaceuticals, Inc. said it filed its delayed 10-Q report for the second quarter of 2006 ended June 30 and therefore regained compliance with Nasdaq's requirements for continued listing on the Nasdaq Stock Market.

In addition to the second-quarter 10-Q, the company filed an amended 10-K report for the year ended Dec. 31, 2005 and an amended 10-Q report for the quarter ended March 31.

Kos received a notice of non-compliance in August following a delay in the filing of the second-quarter 10-Q with the Securities and Exchange Commission due to an internal review of documents related to the grant and exercise of options from Jan. 1, 1997 to the present.

Kos is an integrated specialty pharmaceutical company based in Cranbury, N.J., that develops, commercializes, manufactures and markets prescription products for the treatment of chronic diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.